Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort.

MRD-window ctDNA positivity was 8.1% (34/420) in stage II and 24.9% (126/505) in stage III, with DFS HR 10.4 and 10.1, respectively (both P<0.0001). Combined 24-month DFS was 91.7% if MRD-negative vs 41.4% if MRD-positive. During surveillance, conversion to ctDNA-positive was associated with markedly worse DFS in both observation and ACT-treated patients (stage II observation HR 34.9; stage III ACT HR 54.6).

ASCO Gastrointestinal Cancers Symposium 2025